Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | NOS1 | P29475 | 2/20 | 0.50 |
| ▸ | DRD4 | P21917 | 2/20 | 0.49 |
| ▸ | DRD3 | P35462 | 2/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | LSS | P48449 | 1/20 | 0.48 |
| ▸ | PRMT1 | Q99873 | 3/20 | 0.47 |
| ▸ | F2 | P00734 | 2/20 | 0.47 |
| ▸ | ST14 | Q9Y5Y6 | 2/20 | 0.47 |
| ▸ | PLAU | P00749 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.47 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.47 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.47 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.47 |
| ▸ | PTP4A3 | O75365 | 1/20 | 0.47 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.47 |
| ▸ | F10 | P00742 | 1/20 | 0.47 |
| ▸ | PLG | P00747 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6753836 | 1.00 | ATM (0.51) | ATML3MBTL1NOS1DRD4DRD3 | |
| SCHEMBL6132633 | 1.00 | ATM (0.51) | ATML3MBTL1NOS1DRD4DRD3 | |
| SCHEMBL6132620 | 1.00 | ATM (0.51) | ATML3MBTL1NOS1DRD4DRD3 | |
| SCHEMBL5841721 | 0.98 | L3MBTL1 (0.53) | ATML3MBTL1NOS1DRD4DRD3 | |
| SCHEMBL4828609 | 0.94 | KDM4E (0.48) | ATML3MBTL1NOS1DRD4DRD3 | |
| SCHEMBL7338768 | 0.94 | KDM4E (0.48) | ATML3MBTL1NOS1DRD4DRD3 | |
| SCHEMBL7333008 | 0.94 | KDM4E (0.48) | ATML3MBTL1NOS1DRD4DRD3 | |
| SCHEMBL7334762 | 0.94 | KDM4E (0.48) | ATML3MBTL1NOS1DRD4DRD3 | |
| SCHEMBL10390074 | 0.92 | ATM (0.46) | ATML3MBTL1NOS1DRD4DRD3 | |
| SCHEMBL7147877 | 0.92 | KDM4E (0.49) | ATML3MBTL1NOS1DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20220378726-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ENHANCER OF ZESTE HOMOLOG 2 POLYPEPTIDE | ARVINAS OPERATIONS, INC. | 2022-12-01 | — | — | US | disclosed |
| US-11191741-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | ARVINAS OPERATIONS, INC. (US) | 2021-12-07 | — | — | US | disclosed |
| EP-3558974-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ENHANCER OF ZESTE HOMOLOG 2 POLYPEPTIDE | Arvinas Operations, Inc. (US) | 2019-10-30 | — | — | EP | disclosed |
| US-20180177750-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ENHANCER OF ZESTE HOMOLOG 2 POLYPEPTIDE | ARVINAS OPERATIONS, INC. | 2018-06-28 | — | — | US | disclosed |
| WO-2018119357-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ENHANCER OF ZESTE HOMOLOG 2 POLYPEPTIDE | Arvinas, Inc. (US) | 2018-06-28 | — | — | WO | disclosed |
| CN-102559169-B | Arborization three-nucleus cyclometallation platinum coordination compound electro-phosphorescent material and application of electro-phosphorescent material in polymer electroluminescence white light emitting device | UNIV XIANGTAN | 2014-04-16 | — | — | CN | disclosed |
| CN-102559169-A | Arborization three-nucleus cyclometallation platinum coordination compound electro-phosphorescent material and application of electro-phosphorescent material in polymer electroluminescence white light emitting device | UNIV XIANGTAN | 2012-07-11 | — | — | CN | disclosed |
| US-20110245429-A1 | Cross Linked Organic Conductive Layer | GOUGH, NEIL (GB) | 2011-10-06 | — | — | US | disclosed |
| US-6884868-B1 | Cyclic hexapeptides having antibiotic activity | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-04-26 | — | — | US | disclosed |
| US-6706739-B2 | TREATING ENTEROVIRUS INFECTION | NATIONAL HEALTH RESEARCH INSTITUTE (TW) | 2004-03-16 | — | — | US | disclosed |
| US-20030087936-A1 | Imidazolidinone compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2003-05-08 | — | — | US | disclosed |
| EP-1173472-A1 | CYCLIC HEXAPEPTIDES HAVING ANTIBIOTIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-01-23 | — | — | EP | disclosed |
| WO-2000064927-A1 | CYCLIC HEXAPEPTIDES HAVING ANTIBIOTIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245429-A1 | Cross Linked Organic Conductive Layer | GJB2, GJA1, KCNH3 | ATM 3033/4885L3MBTL1 2464/4885NOS1 2096/4885 |
| US-11191741-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | CRBN, MDM2, VHL | ATM 2133/4885L3MBTL1 401/4885NOS1 4617/4885 |
| US-20220378726-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ENHANCER OF ZESTE HOMOLOG 2 POLYPEPTIDE | CRBN, MDM2, VHL | ATM 2133/4885L3MBTL1 401/4885NOS1 4617/4885 |
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | CRBN, MDM2, VHL | ATM 2133/4885L3MBTL1 401/4885NOS1 4617/4885 |
| US-20180177750-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ENHANCER OF ZESTE HOMOLOG 2 POLYPEPTIDE | CRBN, MDM2, VHL | ATM 2133/4885L3MBTL1 401/4885NOS1 4617/4885 |
| US-20030087936-A1 | Imidazolidinone compounds | EIF2AK2, ZC3HAV1, EMG1 | ATM 2522/4885L3MBTL1 252/4885NOS1 4515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.